63
Participants
Start Date
August 6, 2019
Primary Completion Date
July 5, 2022
Study Completion Date
July 21, 2022
TEV-50717
Dosage ranging from 6 mg to 48 mg.
Placebo
Dosage ranging from 6 mg to 48 mg.
Teva Investigational Site 37102, Woluwe-Saint-Lambert
Teva Investigational Site 37100, Luxembourg City
Teva Investigational Site 39058, Copenhagen
Teva Investigational Site 14225, New York
Teva Investigational Site 80145, Safed
Teva Investigational Site 31259, Córdoba
Teva Investigational Site 14123, Rochester
Teva Investigational Site 31256, Granada
Teva Investigational Site 14293, Washington D.C.
Teva Investigational Site 30214, Milan
Teva Investigational Site 58310, Vinnytsia
Teva Investigational Site 14223, Richmond
Teva Investigational Site 31255, Madrid
Teva Investigational Site 31257, Madrid
Teva Investigational Site 14299, Charleston
Teva Investigational Site 14136, Atlanta
Teva Investigational Site 14291, Atlanta
Teva Investigational Site 14130, Savannah
Teva Investigational Site 14127, Miami
Teva Investigational Site 14125, Tampa
Teva Investigational Site 14137, Birmingham
Teva Investigational Site 14129, Nashville
Teva Investigational Site 31258, Seville
Teva Investigational Site 31254, Valencia
Teva Investigational Site 58313, Dnipropetrovsk
Teva Investigational Site 30217, Florence
Teva Investigational Site 14226, Saint Paul
Teva Investigational Site 30216, Pisa
Teva Investigational Site 53433, Gmina Strzelin
Teva Investigational Site 58312, Kharkiv
Teva Investigational Site 58311, Odesa
Teva Investigational Site 14134, Lincoln
Teva Investigational Site 80147, Ẕerifin
Teva Investigational Site 14228, Houston
Teva Investigational Site 14224, Phoenix
Teva Investigational Site 14295, San Diego
Teva Investigational Site 14227, Loma Linda
Teva Investigational Site 14348, Portland
Teva Investigational Site 14135, Everett
Teva Investigational Site 50473, Moscow
Teva Investigational Site 50470, Moscow
Teva Investigational Site 50469, Smolensk
Teva Investigational Site 50477, Kazan'
Teva Investigational Site 50485, Nizhny Novgorod
Teva Investigational Site 50474, Tyumen
Teva Investigational Site 50468, Novosibirsk
Teva Investigational Site 50475, Khabarovsk
Teva Investigational Site 50478, Stavropol
Teva Investigational Site 80146, Tel Aviv
Teva Investigational Site 80144, Jerusalem
Teva Investigational Site 14290, New Orleans
Teva Investigational Site 14122, Gibbsboro
Teva Investigational Site 14297, New Brunswick
Teva Investigational Site 11165, Nepean
Teva Investigational Site 30213, Napoli
Teva Investigational Site 30215, Roma
Teva Investigational Site 30212, Roma
Teva Investigational Site 53434, Gdansk
Teva Investigational Site 53428, Gdansk
Teva Investigational Site 53427, Krakow
Teva Investigational Site 53431, Lublin
Teva Investigational Site 53432, Poznan
Teva Investigational Site 53430, Wiązowna
Teva Investigational Site 62054, Banská Bystrica
Teva Investigational Site 62053, Dubnica nad Váhom
Teva Investigational Site 58309, Kyiv
Teva Investigational Site 34246, Bristol
Teva Investigational Site 34245, Edinburgh
Teva Investigational Site 34243, London
Teva Investigational Site 34244, Sheffield
Teva Branded Pharmaceutical Products R&D, Inc.
INDUSTRY